ANKDD1A and central nervous system cancer: By MethPrimer analysis, we found that the ANKDD1A promoter contained a CpG island (region −400 bp to +400 bp from transcription start site; Fig. 1d), indicating that hypermethylation may cause the decreased expression of ANKDD1A in glioma.